GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Nemaura Medical Inc (OTCPK:NMRD) » Definitions » PE Ratio (TTM)

NMRD (Nemaura Medical) PE Ratio (TTM) : At Loss (As of Dec. 14, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Nemaura Medical PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-12-14), Nemaura Medical's share price is $0.0002. Nemaura Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.39. Therefore, Nemaura Medical's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Nemaura Medical's PE Ratio (TTM) or its related term are showing as below:

NMRD' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



NMRD's PE Ratio (TTM) is ranked worse than
100% of 401 companies
in the Medical Devices & Instruments industry
Industry Median: 29.02 vs NMRD: At Loss

Nemaura Medical's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.07. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.39.

As of today (2024-12-14), Nemaura Medical's share price is $0.0002. Nemaura Medical's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.63. Therefore, Nemaura Medical's PE Ratio without NRI for today is At Loss.

Nemaura Medical's EPS without NRI for the three months ended in Dec. 2023 was $-0.12. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.63.

During the past 3 years, the average EPS without NRI Growth Rate was -44.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -40.60% per year.

During the past 10 years, Nemaura Medical's highest 3-Year average EPS without NRI Growth Rate was -14.90% per year. The lowest was -48.70% per year. And the median was -38.10% per year.

Nemaura Medical's EPS (Basic) for the three months ended in Dec. 2023 was $-0.07. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.39.


Nemaura Medical PE Ratio (TTM) Historical Data

The historical data trend for Nemaura Medical's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nemaura Medical PE Ratio (TTM) Chart

Nemaura Medical Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
PE Ratio (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Nemaura Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Nemaura Medical's PE Ratio (TTM)

For the Medical Devices subindustry, Nemaura Medical's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nemaura Medical's PE Ratio (TTM) Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Nemaura Medical's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Nemaura Medical's PE Ratio (TTM) falls into.



Nemaura Medical PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Nemaura Medical's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=0.0002/-0.390
=At Loss

Nemaura Medical's Share Price of today is $0.0002.
Nemaura Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.39.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Nemaura Medical  (OTCPK:NMRD) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Nemaura Medical PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Nemaura Medical's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Nemaura Medical Business Description

Traded in Other Exchanges
N/A
Address
57 West 57th Street, New York, NY, USA, 10019
Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.
Executives
Bashir Timol director, 10 percent owner, officer: Chief Business Officer C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Chowdhury Dewan Fazlul Hoque director, 10 percent owner, officer: CEO & President CHAMWOOD BUILDING, HOLYWELL PARK, ASHBURY ROAD, LOUGHBOROUGH LEICS X0 LE113AQ
Salim Natha director LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF
Justin James Mclarney officer: Chief Financial Officer C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Sufyan Ismail 10 percent owner C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Thomas Peter Moore director C/O NEMAURA MEDICAL, INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Timothy Christopher Johnson director C/O NEMAURA MEDICAL INC., 57 WEST 57TH STREET, MANHATTAN NY 10019
Iain Anderson officer: CFO LOUGHBOROUGHUNIVERSITYSCIENCE&ENTERPRISE, PARKS, 5 OAKWOOD DRIVE, LOUGHBOROUGH, LEICESTERSHIRE X0 LE113QF
Kathryn Farrar officer: Director of Finance C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Julie Pomeroy officer: Director of Finance C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT
Richard Toon officer: Technical & Bus. Dev. Manager C/O ONE E GROUP LIMITED, UNIT 3A, SPRINGFIELD COURT, SUMMERFIELD ROAD, BOLTON X0 BL32NT